Disease Areas

Prostate/PSMA

Prostate cancer is the most commonly diagnosed male cancer and a leading cause of death in men. Worldwide, more than 1.4 million men were diagnosed in 2020, and >375,000 died from their disease (WHO, 2020).

Kidney/CAIX

Renal cell carcinoma is the most common and aggressive form of kidney cancer. Renal cell carcinoma is an increasingly frequent cancer, having more than doubled in incidence in the developed world over the last 50 years (Padala et al, World Journal of Oncology, 2020). Worldwide, there were more than ~400,000 new cases in 2020, and >175,000 people died from their disease (WHO, 2020).

Brain/LAT-1

Glioblastoma (GBM) is the most common and aggressive form of primary brain cancer. Worldwide, more than 300,000 people were diagnosed with brain or central nervous system cancer in 2020, and 250,000 died from their disease (WHO, 2020).

Sarcoma/PDGFRα

The targeting of activated fibroblasts in the tumour micro-environment is a promising strategy to elucidate durable treatment responses in certain solid tumors.

Telix’s TLX300 program consists of antibody-directed targeted radiation for both diagnostic and therapeutic applications, against platelet-derived growth factor receptor alpha, or PDGFRα.

Rare disease and Bone marrow Conditioning/CD66

The indications for bone marrow transplantation are increasing from haematological malignancies to solid tumours and autoimmune conditions.

Traditional conditioning regimens are associated with morbidity and mortality from chemotherapy, limiting their use particularly in paediatric and rare diseases.